Trastuzumab emtansine: mechanisms of action and drug resistance
about
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansinePredictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agentsAntibody-drug conjugates--an emerging class of cancer treatmentMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerTargeted therapy for advanced gastric cancer: A review of current status and future prospectsDevelopment, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerWhether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunctionSafety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsTargeted nanodiamonds for identification of subcellular protein assemblies in mammalian cells.Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancerBioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models.Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signalingDownregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors.Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand.Biomarkers and novel agents in esophago-gastric cancer: are we making progress?Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.The role of neratinib in HER2-driven breast cancer.BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line ModelDeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents.Targeted therapies in gastric cancer treatment: where we are and where we are going.Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Antibody drug conjugates.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.
P2860
Q26747729-416752E1-F427-44AC-BE31-53C07EE498BCQ26748931-141D9EF0-F0DC-4E20-BC99-42D5B969B97FQ26770312-6B3A3102-6D5B-404E-85C8-939DF7F6329FQ26772969-E36F96D2-9B6B-4210-A900-1056BF181C50Q26774138-44A758C3-6C4A-4C20-8A4D-7EE8B51D405DQ26778957-FAD83EBF-AB18-48A8-B920-3598C9257605Q26785612-52C5024F-014C-4740-9EC2-12C8195A650BQ28067696-4B266C01-E372-4757-BDB0-2A9CEEE215B5Q28546477-C6A23DA9-0BB1-4A9C-911B-B4F297DC0EE6Q33421995-E32AE331-952F-4D17-825C-7C8A97EA669CQ33430735-17838470-274B-4360-AFE4-B744F89CFA99Q33873317-AC66C7A6-C177-421D-8511-0C66AC50BE6FQ36273796-8830AF76-CF19-40C6-9CD6-BB2951974E8AQ36411392-192CDBD1-FE25-4536-AB7D-C78EC57203D6Q36427101-7FB8B934-D600-4693-8A04-34CAF084CE56Q36557500-2A073DF2-8430-4416-9B5B-C03E4CFEFF36Q36653094-CEFD5077-7BAF-46AE-B2FE-0E0A605262DEQ36789848-6A274887-F122-4FAB-B1E6-BD3BF936A118Q36820693-F0CDD6BA-7AF3-4285-BF72-98E0F49F584DQ37124053-3EFADC19-3B19-4DD8-8CAF-E2F6BABA3A36Q37317395-0FE4FED5-81D8-4B08-8FF4-B00CB176045CQ37600390-91D08F03-D63D-4AF2-AFB4-670270D16107Q37657607-A970FCA4-9370-413C-9EA3-0990E27CACF6Q37709032-08A23F1F-98DB-45FD-A0EE-CBB50BF91FF5Q38399446-6727FA64-2DC2-4CC5-B9AA-810EAC6626BEQ38408138-336AEB1D-8F72-4C50-8D2B-6A1D8A5CBDD8Q38575013-C059F6D8-F3BB-4106-B8DA-A10792DBE225Q38645927-64898555-A853-47FD-B0CD-F222719072BFQ38653626-950A134E-31EE-4A4A-B238-27645E174D09Q38664492-16056C23-0307-4006-8171-135E244DBD5FQ38694128-A7A6E094-72CE-4719-88E4-8F3EA4278A8CQ38725127-B8E2ACB1-512B-4D39-8B61-17559CDF2987Q38731943-FCDDC697-7F94-4909-A7EB-38C131AF8DF1Q38736346-46BE3653-75B7-480F-852D-5E2EB7868393Q38838757-C9F92383-4946-473A-BEE4-E820F987E853Q38873862-CDD65707-A70E-433F-B900-3F30C1E52F39Q38979784-E61840D7-2B7D-4F25-9289-D1220FE6379AQ39045763-32B92B3E-44CD-4FDD-92DC-98E31DAA21C3Q39456292-92FDB286-5767-4897-87C7-ACDBACEF8095Q41282870-5199B390-31DF-409E-A3EC-F7AFF390FA38
P2860
Trastuzumab emtansine: mechanisms of action and drug resistance
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Trastuzumab emtansine: mechanisms of action and drug resistance
@ast
Trastuzumab emtansine: mechanisms of action and drug resistance
@en
type
label
Trastuzumab emtansine: mechanisms of action and drug resistance
@ast
Trastuzumab emtansine: mechanisms of action and drug resistance
@en
prefLabel
Trastuzumab emtansine: mechanisms of action and drug resistance
@ast
Trastuzumab emtansine: mechanisms of action and drug resistance
@en
P2860
P921
P356
P1476
Trastuzumab emtansine: mechanisms of action and drug resistance
@en
P2093
Jorma Isola
Mark Barok
P2860
P2888
P356
10.1186/BCR3621
P5008
P577
2014-03-05T00:00:00Z
P5875
P6179
1021348516